{
  "nctrialId": "HC-1394",
  "title": "A Randomized Double-Blind, Placebo-Controlled Multi-Center Study of DRM-581 (IL-17 inhibitor) in Patients With Crohn's Disease",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled Multi-Center Study of DRM-581 (IL-17 inhibitor) in Patients With Crohn's Disease",
  "sponsor": "Ottawa Hospital Research Institute",
  "indication": "Crohn's Disease",
  "phase": "Phase 3",
  "fileName": "HC-1394.json",
  "fileSize": 186239,
  "date": "2023-10-15",
  "completionDate": "2028-12-27",
  "drugName": "DRM-581 (IL-17 inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Withdrawn",
  "description": "This is a randomized double-blind, placebo-controlled multi-center study designed to evaluate the efficacy and safety of DRM-581 (IL-17 inhibitor) in patients with Crohn's Disease. The study will enroll approximately 194 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 26-80 years\n- Confirmed diagnosis of Crohn's Disease\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1394"
}